Ignite Creation Date:
2024-05-06 @ 5:39 PM
Last Modification Date:
2024-10-26 @ 2:33 PM
Study NCT ID:
NCT05387785
Status:
UNKNOWN
Last Update Posted:
2022-06-10
First Post:
2022-05-17
Brief Title:
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
Sponsor:
Angion Biomedica Corp
Organization:
Angion Biomedica Corp
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-Controlled 2-Period 2-Arm 4-Sequence Crossover Phase 1b Study to Assess the Safety Tolerability and Pharmacokinetics of Ang-3070 in Subjects With Idiopathic Pulmonary Fibrosis Who Are Treatment-Naïve or Who Have Failed or Refused Standard of Care Treatment
Status:
UNKNOWN
Status Verified Date:
2022-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess safety and tolerability of once daily QD and twice daily BID dosing of ANG-3070 in subjects with idiopathic pulmonary fibrosis IPF who are treatment-naïve refused therapy or discontinued for any reason current standard of care with nintedanib or pirfenidone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None